PAS
BNTX icon

Park Avenue Securities’s BioNTech BNTX Stock Holding History

Park Avenue Securities’s Portfolio BNTX Stock Details BNTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-2,176
Closed -$201K – 1363
2024
Q1 		$201K Buy
+2,176
New +$209K ﹤0.01% 1323

Other funds holding BNTX

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Flossbach Von Storch
Flossbach Von Storch Cologne, Germany $21.4B AUM 8.31% 1-Year Est. Return
HL
Harding Loevner Bridgewater, New Jersey $9.72B AUM 22.38% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Park Avenue Securities's BNTX Position: Q2 2024 in Review

Park Avenue Securities sold out of BioNTech (BNTX) in Q2 2024, closing a stake of 2,176 shares — an estimated $201K sold.

Park Avenue Securities first reported a position in BNTX in Q1 2024 and held it in 1 quarter. The position peaked at $201K in Q1 2024. 286 funds tracked by Wall St. Rank hold BNTX as of Q2 2024.

  • Park Avenue Securities reported no remaining BioNTech position as of Q2 2024 after selling out during the quarter.
  • Park Avenue Securities sold 2,176 BioNTech shares in Q2 2024, an estimated $201K.
  • Park Avenue Securities first reported a position in BioNTech in Q1 2024 and held it in 1 quarter.
  • Park Avenue Securities's BioNTech position peaked at $201K in Q1 2024.
  • 286 funds tracked by Wall St. Rank held BioNTech as of Q2 2024.

Based on Park Avenue Securities's 13F filing for Q2 2024, filed 9 Jul 2024.